Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Reported Friday, AbCellera's ABCL575 Matches Clinical Benchmark And Demonstrates Extended Half-Life In Preclinical AD Studies

Author: Benzinga Newsdesk | May 12, 2025 02:40am
  • ABCL575 is a novel, half-life extended anti-OX40L monoclonal antibody that is being developed for the treatment of moderate-to-severe atopic dermatitis (AD)
  • In preclinical studies, ABCL575 shows potent inhibition of inflammatory pathways, favorable in vivo pharmacokinetics (PK), and potential for less frequent dosing compared to a clinical benchmark

Posted In: ABCL


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist